Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review

Show other versions (1)

Background Tocilizumab is an IL-6 receptor-blocking agent proposed for the treatment of severe COVID-19. The aim of this systematic review was to describe the rationale for the use of tocilizumab for the treatment of COVID-19 and to summarize the available evidence regarding its efficacy and safety....

Full description

Bibliographic Details
Published in:Pulmonology
Main Authors: A. Cortegiani, M. Ippolito, M. Greco, V. Granone, A. Protti, C. Gregoretti, A. Giarratano, S. Einav, M. Cecconi
Format: Article
Language:English
Published: Taylor & Francis Group 2021-01-01
Subjects:
COVID-19
Tocilizumab
SARS-CoV-2
Pneumonia
Coronavirus
Online Access:https://www.tandfonline.com/doi/10.1016/j.pulmoe.2020.07.003

Internet

https://www.tandfonline.com/doi/10.1016/j.pulmoe.2020.07.003

Similar Items